GlassScriptPhysician profile
Shil Kiritkumar Patel
NPI 1750541553
$16,286.34
in general payments reported to CMS, 2019-2025
22 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $439 · 2021: $3,963 · 2022: $1,947 · 2023: $8,047 · 2024: $512 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,990 · Food and Beverage: $2,425 · Travel and Lodging: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,990.00 |
| Food and Beverage | $2,424.95 |
| Travel and Lodging | $1,016.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,885.97 | 2019-2025 | Vabysmo, Susvimo |
| Allergan, INC. | $3,593.10 | 2019-2021 | |
| Abbvie INC. | $1,309.15 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,268.23 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $222.44 | 2022-2025 | Xipere, Visudyne |
| Apellis Pharmaceuticals, INC. | $168.98 | 2022-2023 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $151.58 | 2022 | |
| Eyepoint US, INC. | $75.83 | 2019-2022 | |
| Biogen, INC. | $75.04 | 2022 | |
| Alimera Sciences, INC. | $62.59 | 2021-2022 | |
| Harrow Eye, LLC | $62.55 | 2025 | Iheezo |
| Mallinckrodt Hospital Products INC. | $59.68 | 2022-2023 | Acthar |
| Ani Pharmaceuticals, INC. | $57.36 | 2025 | Iluvien, Yutiq |
| Coherus Oncology, INC. | $54.77 | 2022-2023 | |
| Astellas Pharma US INC | $52.95 | 2023-2025 | Izervay |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.89 | 2019-2020 | |
| Genentech, INC. | $37.63 | 2023 | Vabysmo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.06 | 2021 | |
| Spark Therapeutics, INC. | $20.15 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Boston Scientific Corporation | $12.51 | 2022 | |
| Baudax Bio INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.